What's New
Anti-CD20 monoclonal antibodies and the possible risk of pyoderma gangrenosum
Medsafe has published a new monitoring communication to encourage reporting of pyoderma gangrenosum with anti-CD20 monoclonal antibodies (rituximab, ocrelizumab, obinutuzumab, ofatumumab). Anyone can submit a report
News and Events
| Date | Type | Title |
|---|---|---|
| 16/1/2025 | Notices | Updates to the Data sheet template and explanatory guide |
| 16/1/2025 | Monitoring Communication |  Anti-CD20 monoclonal antibodies (rituximab, ocrelizumab, obinutuzumab, ofatumumab) and the possible risk of pyoderma gangrenosum - Monitoring closes 16 July 2025 |
| 7/1/2025 | Notices | Notice of Medsafe Office Closure Christmas/New Year 2024/2025 |
| 17/12/2024 | Consultation | Proposal to change the regulatory and funding restrictions for stimulant treatments for ADHD |
| 5/12/2024 | Publications | Prescriber Update Vol. 45. No. 4 - December 2024 |
